IDH1 Mutation Analysis
Sanger sequencing of IDH1 exon 4 mutations including R132 to inform IDH inhibitor treatment decisions.
Sanger sequencing of IDH1 exon 4 mutations including R132 to inform IDH inhibitor treatment decisions.
Sanger sequencing of IDH2 exon 4 mutations at codons R140 and R172 to inform IDH inhibitor treatment decisions.
Sanger sequencing of ABL1 tyrosine kinase domain to detect imatinib resistance mutations in BCR::ABL1-positive CML, ALL, and AML.
NGS deep sequencing of IGHV to determine somatic hypermutation status, an independent prognostic marker in CLL.
PCR fragment-length analysis detecting clonal IGH rearrangements (FR1, FR2, FR3) for B-cell lymphoma diagnosis and monitoring.
PCR fragment analysis of JAK2 exon 12 insertion/deletion and K539L mutations for myeloproliferative neoplasm diagnosis.
PCR fragment-length analysis of clonal IGK rearrangements for B-cell lymphoma diagnosis and minimal residual disease monitoring.
Qualitative RQ-PCR identification of BCR::ABL1 fusion transcript breakpoint type (major p210 vs minor p190) for diagnosis of CML, ALL, and AML.
Sanger sequencing detection of the BRAF V600E mutation for hairy cell leukemia diagnosis and monitoring.
PCR fragment-length analysis of CALR exon 9 insertion/deletion mutations for myeloproliferative neoplasm diagnosis and monitoring.


